Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

231 results about "Variant strain" patented technology

Pseudorabies virus gD protein as well as preparation method and application thereof

The invention discloses a pseudorabies virus variant gD protein as well as a preparation method and application thereof. The amino acid sequence of the pseudorabies virus variant gD protein is shown as a sequence 1 in a sequence table, and the nucleotide sequence of the pseudorabies virus variant gD protein is shown as a sequence 2 in the sequence table. The pseudorabies virus variant gD protein is used for indirect ELISA, can be used for detecting whether a pseudorabies virus variant gD protein antibody exists in pig blood or not, and is simple, convenient and rapid in detection, high in specificity, high in sensitivity, accurate and reliable. The pseudorabies virus variant gD protein can be prepared into a subunit vaccine, can be induced to generate a high-level anti-pseudorabies virus variant neutralizing antibody after immunizing a pig, has the advantages of strong immunogenicity, high safety and matching with a current epidemic strain, can distinguish vaccine immunization and wild virus infection animals through differential diagnosis, and has a wide application prospect. The method can be used for preventing and controlling the propagation and prevalence of pseudorabies. The gD protein of the pseudorabies virus variant can be used for detecting and diagnosing pseudorabies and preventing pseudorabies, and has good production and application prospects in development of novel diagnostic reagents and subunit vaccines of pseudorabies viruses.
Owner:CHINA ANIMAL HUSBANDRY IND

Recombinant novel coronavirus Omicron variant RBD trimer antigen, immunogenic composition containing same and application of recombinant novel coronavirus Omicron variant RBD trimer antigen

The invention relates to a novel coronavirus recombinant chimeric antigen, a related product thereof, a preparation method and application of the novel coronavirus recombinant chimeric antigen in preparation of a novel coronavirus vaccine. The recombinant chimeric antigen is a recombinant new coronavirus Omicron variant RBD trimer antigen, various types of vaccines based on the recombinant chimeric antigen can induce strong immune response aiming at various subtype variants (including BA.1, BA.2, BA.5, XBB, EG.5, BA.2. 86, JN.1, KP.2 and the like) of the new coronavirus Omicron, and particularly, compared with a protein vaccine of the recombinant chimeric antigen, the recombinant chimeric antigen can induce strong immune response. The mRNA vaccine based on the recombinant chimeric antigen can induce an organism to generate obviously higher RBD specific binding antibody level and neutralizing antibody level, so that the mRNA vaccine can be used as a candidate of a new generation of new coronavirus vaccines, and has potential clinical application value and prospect.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (nitrosamine) protein tandem as target and preparation method thereof

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Neutralizing antibody GR12 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR12

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV +1

Nlr plug-in gene for improving disease resistance of plants and application thereof

The application discloses an NLR plug-in gene for improving plant disease resistance and application thereof, and belongs to the field of plant molecular biology and biotechnology.The NLR plug-in gene StEM1 has a whole gene sequence as shown in SEQ ID NO.1 and a CDS sequence as shown in SEQ ID NO.2, and the amino acid sequence of the encoded protein is as shown in SEQ ID NO.3.The gene plays a key role in improving plant disease resistance, especially resistance to field late blight variant bacteria.In the NLR background, overexpression of the gene significantly promotes the disease resistance of tobacco and potato to pathogenic pythium, and the gene is a gene for enhancing plant disease resistance by improving ETI immunity.Overexpression of the gene in the NLR background is obtained by a genetic transformation method, and a strain line is obtained to resist field variant strains, so as to cope with field diseases of crops.The application provides an excellent gene resource for green prevention and control of late blight and disease-resistant genetic engineering breeding.
Owner:SANYA INSTITUTE OF NANJING AGRICULTURAL UNIVERSITY +1

Porcine reproductive and respiratory syndrome virus recombinant nanoparticle vaccine as well as preparation method and application thereof

The invention discloses a porcine reproductive and respiratory syndrome virus recombinant nanoparticle vaccine and a preparation method and application thereof, the vaccine contains a recombinant nanoparticle protein, and the protein comprises: (1) a recombinant protein designed based on a PRRSV structural protein epitope; (2) nano-particle protein designed on the basis of ferritin derived from bacteria; and (3) realizing the self-assembly of the recombinant nano particles by virtue of a SpyCatcher-SpyTag system. The vaccine can prevent and control NADC30PRRSV-like strains which are popular in China in recent years, and is used for suppressing propagation of PRRSV variants.
Owner:NANJING AGRICULTURAL UNIVERSITY

Neutralizing antibody GR75 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR75

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR75 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR75 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR75 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR75 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV +1

Novel coronavirus SARS-CoV-2 mutant vaccine and application

The invention relates to a novel coronavirus SARS-CoV-2 mutant vaccine and application, the vaccine comprises a fusion protein, and the fusion protein comprises: (1) interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2Omicron mutant strain S protein or a functional fragment of the novel coronavirus SARS-CoV-2Omicron mutant strain S protein; and (3) an immunoglobulin Fc region. Molecule and process optimization of the fusion protein comprises improvement of process developability and immunogenicity, and the vaccine can improve immunogenicity and antibody titer of a mutant new crown antigen through convergence mutation design, efficiently generate a neutralizing antibody, significantly improve defense ability to a variant strain, and can be massively and industrially produced.
Owner:LIVZON MABPHARM

Neutralizing antibody GR46 for resisting novel coronavirus SARS-CoV-2 and variant and application of neutralizing antibody GR46

The invention discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application of the novel coronavirus neutralizing antibody GR46. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR46 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR46 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR46 to S-Trimer and RBD under 2-time and 300-time dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR46 has high affinity and dilution stability and is suitable for clinical large-dose administration.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV +1

Primer probe combination for identifying group A streptococcus M1UK strain and application thereof

The invention discloses a primer probe combination for identifying a group A streptococcus M1UK strain and application of the primer probe combination, and belongs to the technical field of streptococcus mutant strain detection. The primer probe combination provided by the invention can specifically amplify the target gene of the M1UK strain. Furthermore, a method for identifying the M1UK strain is designed according to the primer probe combination, the M1UK strain and other group A streptococcus can be effectively distinguished, and besides the advantages of being high in specificity and accurate in detection result, the method is easy, convenient and rapid to operate and high in detection efficiency, labor cost and time cost are reduced, and the method is suitable for popularization and application. The method can realize rapid and effective non-sequencing-dependent variant strain detection, and has important significance in disease prevention and control and improvement of disease treatment efficiency.
Owner:BEIJING CENT FOR DISEASE PREVENTION & CONTROL

Aeromonas hydrophila bacteriophage, bacteriophage preparation and application thereof

The invention belongs to the technical field of microorganisms, and discloses a bacteriophage which comprises a bacteriophage strain M01 with the preservation number of CCTCC M 20251724 or a variant strain of the bacteriophage strain M01. The variant strain and the bacteriophage strain M01 at least have 95% of average nucleotide identity on the genome. The bacteriophage M01 or the variant strain thereof provided by the invention has strong adsorption and lysis effects on aeromonas hydrophila, does not have genes for coding toxin, virulence factor or antibiotic resistance in a genome, and has good temperature stability and acid-base tolerance; the aeromonas hydrophila can be well applied to aquaculture to prevent and / or treat bacterial septicemia and other diseases caused by aeromonas hydrophila infection.
Owner:THIRD INSTITUTE OF OCEANOGRAPHY STATE OCEANI C ADMINISTRATION

Recombinant vector, recombinant baculovirus and preparation method and application thereof

The invention relates to the technical field of biology, and particularly discloses a recombinant vector, a recombinant baculovirus and a preparation method and application of the recombinant vector and the recombinant baculovirus. According to the method for preparing the recombinant vector, pFastBac Dual is adopted as a vector to prepare a recombinant plasmid vector inserted into a VP2 gene of an avian bursal disease virus classic strain, and the recombinant plasmid vector is named as pDual-V1; the method comprises the following steps: preparing a recombinant plasmid vector into which VP2 genes of a classical strain and a variant strain of the avian bursal disease virus are inserted at the same time, and naming the recombinant plasmid vector as pDual-V1-V2; the method comprises the following steps: preparing a recombinant plasmid vector inserted into a group I type 4 fowl adenovirus Fiber-2 gene, and naming the recombinant plasmid vector as pDual-F2; the method comprises the following steps: preparing a recombinant plasmid vector into which a Fiber-2 gene and an avian reovirus sigma C gene sequence are inserted at the same time, wherein the recombinant plasmid vector is named as pDual-F2-sigma C; carrying out double enzyme digestion on the pDual-V1-V2, recovering small fragments, carrying out double enzyme digestion on the pDual-F2-sigma C, recovering large fragments, and then carrying out mixed enzyme ligation. The recombinant baculovirus can express four antigens at the same time, and effective preparation of a multi-combined vaccine is achieved.
Owner:乾元浩生物股份有限公司

High sensitivity DNA linked immunosorbent signal amplification assay (DLISA) for detection of infectious SARS-COV-2 virus and variants

The present disclosure relates to the use of DNA-peptide hybrid molecules to detect target molecules in a sample. In some embodiments, the DNA-peptide hybrid molecules comprise target-specific binding peptides which selectively bind to a target molecule. Kits comprising DNA-peptide hybrid molecules are also provided.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

PCR detection primer, probe and detection kit for identifying PRRSV (Porcine Reproductive and Respiratory Syndrome Virus)

The invention discloses a PCR (polymerase chain reaction) detection primer, a probe and a detection kit for identifying PRRSV (porcine reproductive and respiratory syndrome virus). According to the method, specific primers and probes are designed and screened for a PRRSV conserved gene ORF6, the primers are composed of two nucleotide sequences as shown in SEQ ID No.1-2, and the sequence of the probes is as shown in SEQ ID No.3; the invention further discloses a TaqMan fluorescent quantitative PCR detection kit for identifying the porcine reproductive and respiratory syndrome virus. The TaqMan fluorescent quantitative PCR detection kit comprises a specific primer, a TaqMan probe and a positive control. The specific primer and the probe provided by the invention can be used for rapidly and accurately identifying the PRRSV, have good sensitivity and specificity, effectively overcome the defect that the existing detection method is insufficient in detection coverage on a new variant or a recombinant strain of the PRRSV, and reduce the possibility of false negative leak detection.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Application of CC-115 in preparation of medicine for resisting new coronavirus

The invention provides an application of CC-115 in preparation of an anti-new coronavirus drug. The chemical name of the CC-115 is 1-ethyl-7-[2-methyl-6-(1H-1, 2, 4-triazole-3-yl) pyridine-3-yl]-3, 5-dihydropyrazino [2, 3-b] pyrazine-2 (1H)-ketone, and the structural formula of the CC-115 is shown in the description. An in-vitro Vero cell infection model finds that the CC-115 can inhibit the replication of a new coronavirus (SARS-CoV-2) original strain and an Omicro variant (EG.5.1), and the IC50 (half maximal inhibitory concentration) of the CC-115 aiming at the SARS-CoV-2 original strain is 0.004 [mu] M and 0.005 [mu] M. The CC-115 has the advantages that the CC-115 can inhibit the replication of the SARS-CoV-2 original strain and the Omicro variant (EG.5.1); the CC-115 can be used for research and development of anti-new coronavirus infection drugs, and has a good development prospect.
Owner:ZHEJIANG UNIV

Method for identifying PEDV chimeric virus attenuation based on reverse genetic manipulation and application of screening potential attenuated vaccine

ActiveCN115852042Bpromote diseasePromote intestinal colonizationMicrobiological testing/measurementMicroorganism based processesAttenuated vaccinePathogenicity
The application discloses a PEDV chimeric virus attenuation identification method based on reverse genetic operation and application of screening potential attenuated vaccine, and the PEDV chimeric virus CHM2013-SP BJ , CHM2013- BJ , CHM2013-SP BJ -ORF3 CHM , CHM2013-SP BJ -E CHM , CHM2013-SP BJ -M CHM , CHM2013-SP BJ -N CHM and CHM2013-(S+ORF3) BJ are constructed and rescued, loss-of-function test and gain-of-function test are carried out, and the attenuated chimeric virus CHM2013-SP BJ -ORF3 CHM and CHM2013-SP BJ -M CHM are obtained, and it is disclosed that the S gene of the PEDV variant BJ2011C promotes virus pathogenicity in cooperation with the ORF3, E and M genes, and the ORF3 gene is the most critical.
Owner:CHINA AGRI UNIV

A broad-spectrum neutralizing antibody against novel coronavirus and its application

This invention provides a human antibody with neutralizing ability against the JN.1 variant of SARS-CoV-2 and its application, belonging to the field of biomedical technology. The antibody comprises a heavy chain sequence as shown in SEQ ID NO:1 and a light chain sequence as shown in SEQ ID NO:2; or comprises a heavy chain sequence as shown in SEQ ID NO:3 and a light chain sequence as shown in SEQ ID NO:4. The antibody of this invention binds to the extracellular domain of the JN.1 variant spike protein via ECG. 50 The value was significantly lower than that of its parent antibody, with a binding capacity increase of 3 to 5 times or more. In the pseudovirus neutralization experiment, the antibody showed a half-maximal neutralizing concentration (IC50) against JN.1 pseudovirus. 50 The antibody also showed significantly better performance than the parent antibody, with a neutralizing activity increase of 3 to 24 times or more. Furthermore, the antibody's melting temperature exceeded 75°C, demonstrating good thermal stability.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Foot-and-mouth disease virus type O specific neutralizing swine monoclonal antibody and application thereof

The invention discloses a neutralizing swine monoclonal antibody pO18-40 and a neutralizing swine monoclonal antibody pO18-43 for foot and mouth disease virus type O. The amino acid sequences of a heavy chain variable region (VH) and a light chain variable region (VL) of the antibody pO18-40 are respectively as shown in SEQ ID No. 1 and SEQ ID No. 2; the amino acid sequences of VH and VL of the antibody pO18-43 are respectively as shown in SEQ ID No. 3 and SEQ ID No. 4. The antibody obtained by the invention is a full-swine-source antibody, can specifically neutralize the classical strain of the O-type foot-and-mouth disease virus, and can clearly distinguish the classical strain of the O / Cathay topological type from the variant strain of the O / Cathay topological type. A key antigen epitope recognized by the antibody is located at the 149th amino acid of a VP1 protein G-H ring, and the site is a key site of O / Cathay strain antigen variation and vaccine immune protection. The antibody provided by the invention provides an important tool and theoretical basis for serological detection of O-type FMDV, vaccine immune effect evaluation and optimal design of broad-spectrum vaccines.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Recombinant Marek's disease virus co-expressing Newcastle disease virus F gene and novel variant VP2 gene of infectious bursal disease virus and application of recombinant Marek's disease virus

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and a novel variant VP2 gene of an infectious bursal disease virus and application of the recombinant Marek's disease virus, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus novel variant VP2 gene is inserted between 105561-105563 nucleotides of a serum type 1 chicken Marek's disease virus CVI988 strain genome; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus novel variant VP2 gene expression framework are inserted into a chicken Marek's disease virus genome, and a recombinant virus C20103 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus novel variant VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant chicken Marek's disease virus provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and chicken Marek's disease at the same time, and has a good market application prospect.
Owner:INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI +1

Respiratory syncytial virus F protein mutant and vaccine

The invention discloses a respiratory syncytial virus F protein mutant and a vaccine, and belongs to the technical field of biological medicines. The mutant is capable of inducing a higher neutralizing antibody titer against the respiratory syncytial virus. According to the invention, the amino acid sequence of the RSV pre-fusion protein is mutated and transformed, so that the stability is enhanced, the immunogenicity of the vaccine to different RSV variants is improved, and the protection effect of the vaccine is improved.
Owner:SUZHOU BEREN BIOTECHNOLOGY CO LTD

Application of CC-115 in preparation of medicine for resisting new coronavirus

The invention provides an application of CC-115 in preparation of an anti-new coronavirus drug. The chemical name of the CC-115 is 1-ethyl-7-[2-methyl-6-(1H-1, 2, 4-triazole-3-yl) pyridine-3-yl]-3, 5-dihydropyrazino [2, 3-b] pyrazine-2 (1H)-ketone, and the structural formula of the CC-115 is shown in the description. An in-vitro Vero cell infection model finds that the CC-115 can inhibit the replication of a new coronavirus (SARS-CoV-2) original strain and an Omicro variant (EG.5.1), and the IC50 (half maximal inhibitory concentration) of the CC-115 aiming at the SARS-CoV-2 original strain is 0.004 [mu] M and 0.005 [mu] M. The CC-115 has the advantages that the CC-115 can inhibit the replication of the SARS-CoV-2 original strain and the Omicro variant (EG.5.1); the CC-115 can be used for research and development of anti-new coronavirus infection drugs, and has a good development prospect.
Owner:ZHEJIANG UNIV

Broad-spectrum neutralizing novel coronavirus SARS-CoV-2 nano antibody as well as preparation method and application thereof

The invention discloses a nano antibody for broad-spectrum neutralization of novel coronavirus SARS-CoV-2 as well as a preparation method and application of the nano antibody. The invention also discloses nucleic acid or a gene for coding the nano antibody, an expression cassette, a recombinant vector, a recombinant cell or a recombinant bacterium and application of the nano antibody in preparation of drugs or vaccines for treating diseases infected by the novel coronavirus SARS-CoV-2 or the variant thereof. The amino acid sequence of the nano antibody has the characteristics of small molecular weight, high stability and high affinity, and the nano antibody can be combined with various mutants of S protein RBD to neutralize novel Spike pseudovirus of coronavirus. The invention also relates to the nano antibody and the related product thereof, and the nano antibody and the related product thereof have remarkable binding capacity and broad-spectrum effect in preventing and / or treating related diseases infected by the novel coronavirus and the variant thereof.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL

An anti-swine pseudorabies virus infection preparation and application of radix rehmanniae polysaccharides in preparation of the preparation

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.
Owner:YANGZHOU UNIV

An H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

Compositions, kits, methods of detecting sars-cov-2 and uses thereof

The present application belongs to the field of molecular biology detection; specifically, it relates to the detection of SARS-CoV-2; more specifically, it relates to the detection and typing of SARS-CoV-2 variants. The present application provides a kit comprising the composition, the use of the composition, and a method for detecting SARS-CoV-2 variants and typing. The present application simultaneously realizes the detection and typing of SARS-CoV-2 variants in the reaction system by detecting different characteristic functional mutation sites on SARS-CoV-2 variants, thereby enabling different strains to be treated differently, thus making treatment and prevention more efficient. The composition of the present application is low in cost and high in throughput. Moreover, the operation is simple, and the result reading process can be determined through different channels. The whole detection process is carried out in a closed condition, avoiding false positives and environmental pollution caused by cross-contamination between samples.
Owner:SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION (SHENZHEN HEALTH INSPECTION CENTER SHENZHEN INSTITUTE OF PREVENTIVE MEDICINE) +1

ACE2 modified protein and its application

This invention relates to the field of genetic engineering technology. Specifically, it provides the use of a modified ACE2 protein in the preparation of drugs for treating and / or preventing diseases caused by SARS-like coronaviruses that use ACE2 as a receptor, or in the preparation of vaccines for preventing infection by SARS-like coronaviruses that use ACE2 as a receptor. The modified hACE2 fragment and hFc protein of this invention are antibody-like proteins, which can be widely used to treat diseases caused by the original and variant strains of SARS-CoV-2, and are expected to treat diseases caused by SARS-related coronaviruses or SARS-like coronaviruses that use ACE2 as a receptor.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

Recombinant Meq gene-deficient Marek's disease virus strain expressing varIBDV VP2 gene and its construction method and application

The invention discloses a recombinant vector for expressing varIBDV VP2 gene Meg Gene-deficient Marek's disease virus strain and its construction method and application. Meg The gene-deficient Marek's disease virus strain is obtained by using recombinant cloning technology to insert the gene fragment CMV-VP2 containing the CMV promoter sequence, varIBDV VP2 gene and terminator sequence into the Meg The gene-deleted Marek's disease virus strain rMSΔMeq US2 gene was obtained by replacing the nucleotide sequence between positions 156501-157116 of the rMSΔMeq genome, and was named rMDV-varVP2. Studies have shown that the recombinant obtained by the present invention Meg The gene-deficient Marek's disease virus rMDV-varVP2 has the same in vitro replication ability and good genetic stability as the parent virus rMSΔMeq strain, and rMDV-varVP2 can provide good protection against IBDV mutants after immunizing chickens. The present invention provides a technical means for the development of a recombinant MDV live vector vaccine.
Owner:HARBIN VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES (CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER HARBIN BRANCH CENTER)

COVID-19 composite vaccine based on DNA vector and replicating vaccinia virus vector

The present invention provides a recombinant vaccinia virus that simultaneously expresses the extracellular segment of the S gene of the new coronavirus and the full-length segment of the N gene. The present invention also provides an immunization kit containing the recombinant vaccinia virus, and a DNA vector expressing the extracellular segment of the S gene of the new coronavirus and a DNA vector expressing the full-length segment of the N gene of the new coronavirus as a composite vaccine. By using the three vaccines in the composite vaccine provided by the present invention, the sequential inoculation at 0, 2, and 4 weeks can induce experimental animals to produce CD4, CD8 cell responses specific to the N, S1, and S2 proteins of the new coronavirus, and the CD8T cell response is higher than the CD4T cell response, the induced T cell immunity can last for at least 3 months, and the binding antibody lasts for 6 months without a significant decrease, indicating that the composite vaccine can induce a lasting immune response to SARS-CoV-2, and the neutralizing antibodies induced by the vaccine have cross-reactive activity, which can prevent infection of multiple variants of the new coronavirus to a certain extent.
Owner:NAT CENT FOR AIDSSTD CONTROL & PREVENTION CHINESE CENT FOR DISEASE CONTROL & PREVENTION

Broad-spectrum Anti-covid-19 vaccine immunogen composition, and preparation and use thereof

PCT designated stageWO2025227322A1DepsipeptidesAntiviralsAntigenCell immunity
Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and / or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT

Application of GW4064 in preparation of anti-porcine reproductive and respiratory syndrome virus drugs

The invention relates to the technical field of biological medicine, in particular to application of GW4064 in preparation of drugs for resisting porcine reproductive and respiratory syndrome virus. The invention discloses a novel application of a farnesyl ester X receptor stimulant GW4064 in preparation of a PRRSV (porcine reproductive and respiratory syndrome virus) resisting medicine. The GW4064 has strong antiviral activity on PRRSV (Porcine Reproductive and Respiratory Syndrome Virus), and particularly has a remarkable inhibition effect on a high-pathogenicity strain (HP-PRRSV). The GW4064 interferes with the life cycle of the virus by targeting the NSP3 protein of the PRRSV, so that the replication and propagation of the virus are inhibited. The GW4064 has a remarkable antiviral effect on various variants of the PRRSV, and shows a broad-spectrum antiviral effect. Meanwhile, the GW4064 is small in molecular weight, can easily enter cells, and can efficiently play a role without carrier delivery. The invention also provides a pharmaceutical composition taking GW4064 as a main active component, and a theoretical basis and a practical basis are provided for development of PRRSV antiviral drugs.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY